Stereotactic body radiotherapy of adrenal metastases-A dose-finding study.
SBRT
adrenal
dose-finding
oligometastases
Journal
International journal of cancer
ISSN: 1097-0215
Titre abrégé: Int J Cancer
Pays: United States
ID NLM: 0042124
Informations de publication
Date de publication:
01 08 2022
01 08 2022
Historique:
revised:
22
02
2022
received:
09
01
2022
accepted:
08
03
2022
pubmed:
7
4
2022
medline:
9
6
2022
entrez:
6
4
2022
Statut:
ppublish
Résumé
Optimal doses for the treatment of adrenal metastases with stereotactic radiotherapy (SBRT) are unknown. We aimed to identify dose-volume cut-points associated with decreased local recurrence rates (LRR). A multicenter database of patients with adrenal metastases of any histology treated with SBRT (biologically effective dose, BED10 ≥50 Gy, ≤12 fractions) was analyzed. Details on dose-volume parameters were required (planning target volume: PTV-D98%, PTV-D50%, PTV-D2%; gross tumor volume: GTV-D50%, GTV-mean). Cut-points for LRR were optimized using the R maxstat package. One hundred and ninety-six patients with 218 lesions were included, the largest histopathological subgroup was adenocarcinoma (n = 101). Cut-point optimization resulted in significant cut-points for PTV-D50% (BED10: 73.2 Gy; P = .003), GTV-D50% (BED10: 74.2 Gy; P = .006), GTV-mean (BED10: 73.0 Gy; P = .007), and PTV-D2% (BED10: 78.0 Gy; P = .02) but not for the PTV-D98% (P = .06). Differences in LRR were clinically relevant (LRR ≥ doubled for cut-points that were not achieved). Further dose-escalation was not associated with further improved LRR. PTV-D50%, GTV-D50%, and GTV-mean cut-points were also associated with significantly improved LRR in the adenocarcinoma subgroup. Separate dose optimizations indicated a lower cut-point for the PTV-D50% (BED10: 69.1 Gy) in adenocarcinoma lesions, other values were similar (<2% difference). Associations of cut-points with overall survival (OS) and progression-free survival were not significant but durable freedom from local recurrence was associated with OS in a landmark model (P < .001). To achieve a significant improvement of LRR for adrenal SBRT, a moderate escalation of PTV-D50% BED10 >73.2 Gy (adenocarcinoma: 69.1 Gy) should be considered.
Types de publication
Journal Article
Multicenter Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
412-421Informations de copyright
© 2022 The Authors. International Journal of Cancer published by John Wiley & Sons Ltd on behalf of UICC.
Références
Pardo Aranda F, Larranaga Blanc I, Rivero Deniz J, et al. Surgical treatment of lung cancer with synchronous adrenal metastases: adrenalectomy first. Cir Esp. 2017;95:97-101.
Russo AE, Untch BR, Kris MG, et al. Adrenal metastasectomy in the presence and absence of extraadrenal metastatic disease. Ann Surg. 2019;270:373-377.
Duh QY. Laparoscopic adrenalectomy for isolated adrenal metastasis: the right thing to do and the right way to do it. Ann Surg Oncol. 2007;14:3288-3289.
Buergy D, Rabe L, Siebenlist K, et al. Treatment of adrenal metastases with conventional or hypofractionated image-guided radiation therapy-patterns and outcomes. Anticancer Res. 2018;38:4789-4796.
Plichta K, Camden N, Furqan M, et al. SBRT to adrenal metastases provides high local control with minimal toxicity. Adv Radiat Oncol. 2017;2:581-587.
Celik E, Semrau R, Baues C, Trommer-Nestler M, Baus W, Marnitz S. Robot-assisted extracranial stereotactic radiotherapy of adrenal metastases in oligometastatic non-small cell lung cancer. Anticancer Res. 2017;37:5285-5291.
Desai A, Rai H, Haas J, Witten M, Blacksburg S, Schneider JG. A retrospective review of cyberknife stereotactic body radiotherapy for adrenal tumors (primary and metastatic): Winthrop university hospital experience. Front Oncol. 2015;5:185.
Rudra S, Malik R, Ranck MC, et al. Stereotactic body radiation therapy for curative treatment of adrenal metastases. Technol Cancer Res Treat. 2013;12:217-224.
Ahmed KA, Barney BM, Macdonald OK, et al. Stereotactic body radiotherapy in the treatment of adrenal metastases. Am J Clin Oncol. 2013;36:509-513.
Scorsetti M, Alongi F, Filippi AR, et al. Long-term local control achieved after hypofractionated stereotactic body radiotherapy for adrenal gland metastases: a retrospective analysis of 34 patients. Acta Oncol. 2012;51:618-623.
Holy R, Piroth M, Pinkawa M, Eble MJ. Stereotactic body radiation therapy (SBRT) for treatment of adrenal gland metastases from non-small cell lung cancer. Strahlenther Onkol. 2011;187:245-251.
Casamassima F, Livi L, Masciullo S, et al. Stereotactic radiotherapy for adrenal gland metastases: university of Florence experience. Int J Radiat Oncol Biol Phys. 2012;82:919-923.
Chawla S, Chen Y, Katz AW, et al. Stereotactic body radiotherapy for treatment of adrenal metastases. Int J Radiat Oncol Biol Phys. 2009;75:71-75.
Konig L, Hafner MF, Katayama S, et al. Stereotactic body radiotherapy (SBRT) for adrenal metastases of oligometastatic or oligoprogressive tumor patients. Radiat Oncol. 2020;15:30.
Chen WC, Baal JD, Baal U, et al. Stereotactic body radiation therapy of adrenal metastases: a pooled meta-analysis and systematic review of 39 studies with 1006 patients. Int J Radiat Oncol Biol Phys. 2020;107:48-61.
Burjakow K, Fietkau R, Putz F, Achterberg N, Lettmaier S, Knippen S. Fractionated stereotactic radiation therapy for adrenal metastases: contributing to local tumor control with low toxicity. Strahlenther Onkol. 2019;195:236-245.
Buergy D, Wurschmidt F, Gkika E, et al. Stereotactic or conformal radiotherapy for adrenal metastases: patient characteristics and outcomes in a multicenter analysis. Int J Cancer. 2021;149:358-370.
Schmitt D, Blanck O, Gauer T, et al. Technological quality requirements for stereotactic radiotherapy: expert review group consensus from the dgmp working group for physics and technology in stereotactic radiotherapy. Strahlenther Onkol. 2020;196:421-443.
Guckenberger M, Baus WW, Blanck O, et al. Definition and quality requirements for stereotactic radiotherapy: consensus statement from the degro/dgmp working group stereotactic radiotherapy and radiosurgery. Strahlenther Onkol. 2020;196:417-420.
Gomez DR, Tang C, Zhang J, et al. Local consolidative therapy vs. maintenance therapy or observation for patients with oligometastatic non-small-cell lung cancer: long-term results of a multi-institutional, phase ii, randomized study. J Clin Oncol. 2019;37:1558-1565.
Petrelli F, Comito T, Barni S, et al. Stereotactic body radiotherapy for colorectal cancer liver metastases: a systematic review. Radiother Oncol. 2018;129:427-434.
Kroeze SGC, Fritz C, Basler L, et al. Combination of stereotactic radiotherapy and targeted therapy: patterns-of-care survey in german-speaking countries. Strahlenther Onkol. 2019;195:199-206.
Zhao X, Zhu X, Zhuang H, et al. Clinical efficacy of stereotactic body radiation therapy (SBRT) for adrenal gland metastases: a multi-center retrospective study from China. Sci Rep. 2020;10:7836.
Rieber J, Streblow J, Uhlmann L, et al. Stereotactic body radiotherapy (sbrt) for medically inoperable lung metastases-a pooled analysis of the german working group “stereotactic radiotherapy”. Lung Cancer. 2016;97:51-58.
Andratschke N, Alheid H, Allgauer M, et al. The SBRT database initiative of the german society for radiation oncology (DEGRO): patterns of care and outcome analysis of stereotactic body radiotherapy (SBRT) for liver oligometastases in 474 patients with 623 metastases. BMC Cancer. 2018;18:283.
Gerhard SG, Palma DA, Arifin AJ, et al. Organ at risk dose constraints in SABR: a systematic review of active clinical trials. Pract Radiat Oncol. 2021;11:e355-e365.
Nonaka H, Onishi H, Ozaki M, Kuriyama K, Komiyama T, Saito R. Serious gastric perforation after second stereotactic body radiotherapy for peripheral lung cancer that recurred after initial stereotactic body radiotherapy: a case report. J Med Case Reports. 2017;11:343.
LaCouture TA, Xue J, Subedi G, et al. Small bowel dose tolerance for stereotactic body radiation therapy. Semin Radiat Oncol. 2016;26:157-164.
Goldsmith C, Price P, Cross T, Loughlin S, Cowley I, Plowman N. Dose-volume histogram analysis of stereotactic body radiotherapy treatment of pancreatic cancer: a focus on duodenal dose constraints. Semin Radiat Oncol. 2016;26:149-156.
Brandner ED, Chetty IJ, Giaddui TG, Xiao Y, Huq MS. Motion management strategies and technical issues associated with stereotactic body radiotherapy of thoracic and upper abdominal tumors: a review from NRG oncology. Med Phys. 2017;44:2595-2612.
Franzese C, Franceschini D, Cozzi L, et al. Minimally invasive stereotactical radio-ablation of adrenal metastases as an alternative to surgery. Cancer Res Treat. 2017;49:20-28.
Franzese C, Stefanini S, Massaro M, et al. Phase II trial of stereotactic body radiation therapy on adrenal gland metastases: evaluation of efficacy and impact on hormonal production. J Cancer Res Clin Oncol. 2021;147:3619-3625.
Guckenberger M, Klement RJ, Allgauer M, et al. Applicability of the linear-quadratic formalism for modeling local tumor control probability in high dose per fraction stereotactic body radiotherapy for early stage non-small cell lung cancer. Radiother Oncol. 2013;109:13-20.
Report 91. J ICRU. 2017;14:1-160.
R Core Team. R: A Language and Environment for Statistical Computing. Vienna, Austria: R Foundation for Statistical Computing; 2020.
Gray RJ. A class of k-sample tests for comparing the cumulative incidence of a competing risk. Ann Stat. 1988;16:1141-1154.
Lausen B, Lerche R, Schumacher M. Maximally selected rank statistics for dose-response problems. Biom J. 2002;44:131-147.
Hothorn T. Maxstat: Maximally Selected Rank Statistics. R package version 0.7-25 ed; 2017.
Dutz A, Lock S. Competing risks in survival data analysis. Radiother Oncol. 2019;130:185-189.
Stumpf PK, Yorke ED, El Naqa I, et al. Modeling of tumor control probability in stereotactic body radiation therapy for adrenal tumors. Int J Radiat Oncol Biol Phys. 2021;110:217-226.
Wilke L, Moustakis C, Blanck O, et al. Improving interinstitutional and intertechnology consistency of pulmonary sbrt by dose prescription to the mean internal target volume dose. Strahlenther Onkol. 2021;197:836-846.
de Kuijer M, van Egmond J, Kouwenhoven E, Bruijn-Krist D, Ceha H, Mast M. Breath-hold versus mid-ventilation in SBRT of adrenal metastases. Tech Innov Patient Support Radiat Oncol. 2019;12:23-27.